60 Degrees Pharma Q2 FY26 net loss widens 30.6% to $2.26 million; revenue more than doubles to $207,898
SXTP•Quarterly results
60 Degrees Pharmaceuticals posted a net loss attributable to shareholders of $2.26 million for Q2 2026, widening from $1.73 million a year earlier.
Product Revenues - net of Discounts and Rebates more than doubled to $207,898, up 105.98% year over year.
Operating loss widened to $2.27 million, while gross margin fell 23.09 percentage points to 27.32%.
Business updates during the quarter
The quarter included a Runway Health partnership to expand Arakoda access, an FDA objection on Australian Chestnut Extract marketing, and an FSU patent license.
Cash position and operating cash use
Cash and cash equivalents totaled $1.02 million at June 30, 2026; net cash used in operating activities rose to for H1 2026.
